897 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Buy
Article Searches
GlaxoSmithKline (GSK) Flat As Market Gains: What You Should Know http://www.zacks.com/stock/news/351676/glaxosmithkline-gsk-flat-as-market-gains-what-you-should-know?cid=CS-ZC-FT-351676 Feb 01, 2019 - GlaxoSmithKline (GSK) closed at $39.20 in the latest trading session, marking no change from the prior day.
High Yield Stocks For Investors Looking For Income Options https://seekingalpha.com/article/4236576-high-yield-stocks-investors-looking-income-options?source=feed_all_articles Jan 30, 2019 -
Pfizer's outlook disappoints after Viagra loses patent protection and Lyrica faces same fate https://www.cnbc.com/2019/01/29/pfizer-earnings-q4-2018.html Jan 29, 2019 - Pharmaceutical giant Pfizer braced investors for little-to-no revenue growth in 2019 after its blockbuster erectile dysfunction drug Viagra and others lost patent protection and pain killer Lyrica faces similar competition from generic drugmakers.
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update https://seekingalpha.com/article/4236060-tracking-ken-fishers-fisher-asset-management-portfolio-q4-2018-update?source=feed_all_articles Jan 28, 2019 - Fisher’s 13F portfolio value decreased from $82.37B to $73.22B in Q4 2018.Visa Inc., Amazon.com, Apple Inc., Microsoft, and Pfizer are the largest five individual stock positions.Fisher has substantia
Shionogi's Strong Core Offers More Capital Return Possibilities https://seekingalpha.com/article/4233693-shionogis-strong-core-offers-capital-return-possibilities?source=feed_tag_japan Jan 16, 2019 -
Dynavax Projects HEPLISAV-B Inflection In 2019, While CEO Eddie Gray Continues To Search For SD-101 Partners https://seekingalpha.com/article/4233324-dynavax-projects-heplisav-b-inflection-2019-ceo-eddie-gray-continues-search-sdminus-101?source=feed_sector_healthcare Jan 14, 2019 - Dynavax recently presented a company outlook for 2019 at the JP Morgan Healthcare Conference. During the presentation, CEO Eddie Gray revealed encouraging HEPISLAV-B sales for Q4 of ~$3.7M.2018 was a
Is 2019 The Turnaround Year For Gilead Sciences? https://seekingalpha.com/article/4233225-2019-turnaround-year-gilead-sciences?source=feed_sector_healthcare Jan 14, 2019 - Following precipitous revenue losses attributable to its portfolio of HCV medicines, Gilead finds itself in improving financial straits.2019 will see the release of pivotal data from Phase III clinica
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-ZC-FT-347005 Jan 11, 2019 - Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
New Strong Sell Stocks for January 11th http://www.zacks.com/stock/news/347000/new-strong-sell-stocks-for-january-11th?cid=CS-ZC-FT-347000 Jan 11, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 http://www.zacks.com/stock/news/346884/4-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2019?cid=CS-ZC-FT-346884 Jan 11, 2019 - Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

Pages: 12345678...90

<<<Page 3>